Trial Profile
AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane) in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Jan 2024 Planned End Date changed from 1 Nov 2023 to 1 Jun 2024.
- 01 Jan 2024 Planned primary completion date changed from 1 Nov 2023 to 1 Jun 2024.
- 26 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Nov 2023.